North America to Dominate the PCR Kits Market

Introduction

PCR kits are extensively used in the diagnostics and research of cancer, infectious diseases, and genetic disorders. Technological advancements, development of new PCR kits, and increasing investments in research and development activities drive the market growth. In addition, there is a consistent demand for effective detection techniques owing to rising cases of life-threatening infectious diseases, such as HIV, tuberculosis, malaria, hepatitis, and Staph-related diseases, and genetic disorders. As per the World Health Organization, around 219 million cases of malaria were registered across the world in r 2018, with 92% cases in the African subcontinent.

Key Highlights

• The PCR kit market size was valued at USD 2,350.5 million in 2019 and is expected to grow with a CAGR of 8.0% due to increasing product launches and collaborations to acquire a more significant market share.
• The quantitative PCR kits held the largest market share due to the higher adoption of diagnostic and research laboratories owing to cost-effectiveness and higher efficiency in the diagnosis of infectious diseases.
• The consumables and reagents segment was the largest segment of the PCR kit market in 2019. This can be attributed to the launch of newer products and higher demand for the segment.
• North America dominates the PCR kit market, followed by Europe due to higher healthcare spending, increased adoption of new PCR kits, availability of R&D grants, and large scale commercialization of the kits.

Competitive Players

1. Qiagen N.V
2. Bio-Rad Laboratories, Inc.
3. Thermo Fisher Scientific, Inc.
4. Hoffman-La Roche Ltd.
5. Abbott Laboratories
6. Enzo Life Sciences, Inc.
7. Merck KGaA
8. Biomérieux S.A.
9. Danaher Corporation
10. Quanterix Corporation
11. Becton Dickinson and Company
12. Agilent Technologies, Inc

Recent Developments

Recent Developments

• In January 2019, QIAGEN N.V. acquired FORMULATRIX’s digital PCR assets in a deal valued at USD 260 million. The acquisition has augmented the company’s ability to launch new digital PCR platforms in 2020 by incorporating FORMULATRIX’s advanced Digital PCR technology.
• In January 2019, Abbott signed an eight-year partnership agreement with the Japanese Red Cross Society (JRC) to develop PCR kits for serological testing and quality control, including instruments and reagents and consumables used for blood and plasma screening in Japan. 

Segmentation

1. By Technology
   1. Quantitative PCR
   2. Digital PCR
2. By Product
   1. Consumables and reagents
   2. Instruments
   3. Software
3. By Application
   1. Genetic testing
   2. Infectious disease testing
   3. Oncology
   4. Blood screening
   5. Diagnostic research
   6. Forensics
4. By End-User
   1. Hospitals and diagnostic centers
   2. Pharmaceutical and Biotech companies
   3. Academic research laboratories
   4. Clinical research laboratories
   5. Forensic laboratories